Delafloxacin

Delafloxacin
Clinical data
Trade names	Baxdela, others
Other names	ABT-492; RX-3341; WQ-3034
AHFS/Drugs.com	Monograph
License data	US DailyMed: Delafloxacin;
Routes of; administration	By mouth, intravenous injection
ATC code	J01MA23 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
	IUPAC name 1-(6-amino-3,5-difluoro-2-pyridyl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-quinoline-3-carboxylic acid;
CAS Number	189279-58-1 ; 352458-37-8 (meglumine);
PubChem CID	487101;
DrugBank	DB11943;
ChemSpider	427049;
UNII	6315412YVF;
KEGG	D09330; as salt: D09331;
ChEMBL	ChEMBL2105637;
CompTox Dashboard (EPA)	DTXSID40172331 ;
Chemical and physical data
Formula	C18H12ClF3N4O4
Molar mass	440.76 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Fc4cc(F)c(nc4N1\C=C(\C(=O)O)C(=O)c2c1c(Cl)c(c(F)c2)N3CC(O)C3)N;

Delafloxacin sold under the brand name Baxdela among others, is a fluoroquinolone antibiotic used to treat acute bacterial skin and skin structure infections.^[3] It was developed by Melinta Therapeutics.

^ "Summary Basis of Decision for Baxdela". Drug and Health Products Portal. 2 April 2025. Retrieved 22 June 2025.
^ "Register of Innovative Drugs". Health Canada. 3 November 2006. Retrieved 17 April 2025.
^ ^a ^b Cite error: The named reference Baxdela FDA label was invoked but never defined (see the help page).
^ "Quofenix EPAR". European Medicines Agency (EMA). 16 December 2019. Retrieved 17 October 2024.